Alex Aronov is Senior Director and Head of Data Science at Vertex Pharmaceuticals, a function he co-founded in 2017 to address data-centric problems across the entire business through application of advanced analytics and machine learning.
Previously, Alex led the Discovery Informatics team at Vertex, with responsibility for the high throughput screening content and enrichment, the global chemical genomics initiative, as well as the company’s toxicogenomics efforts. From 2007 to 2012, he led a cross-functional team from lead discovery to late preclinical development that delivered a novel immuno-oncology candidate BVD-723. Alex started his career at Vertex as a computer-aided drug design scientist in 2001, and was involved in projects across a range of therapeutic areas from oncology to inflammation, and from rare diseases to antivirals.
He serves on the Drug Discovery for the Nervous System committee at the Center for Scientific Review/NIH, and is a board member for MIT delta v entrepreneurship bootcamp at the MIT Martin Trust Center.
Alex is an author of over 30 peer-reviewed manuscripts, and is an inventor on over 40 international patent applications. He holds a PhD in chemistry from the University of Washington, and completed postdoctoral training at the University of California, San Francisco School of Pharmacy. He received an MBA from MIT Sloan School of Management.